Literature DB >> 23595044

Resistant hypertension and target organ damage.

Maria Lorenza Muiesan1, Massimo Salvetti, Damiano Rizzoni, Anna Paini, Claudia Agabiti-Rosei, Carlo Aggiusti, Enrico Agabiti Rosei.   

Abstract

Cardiovascular (CV) complications such as myocardial infarction, heart failure, stroke and renal failure are related to both the degree and the duration of blood pressure (BP) increase. Resistant hypertension (RH) is associated with a higher risk of CV complications and a higher prevalence of target organ damage (TOD). The relationship between CV disease and TOD can be bidirectional. Elevated BP in RH may cause CV structural and functional alterations, and the development or persistence of left ventricular hypertrophy, aortic stiffness, atherosclerotic plaques, microvascular disease and renal dysfunction, may render hypertension more difficult to control. Specifically, RH is related to several conditions, including obesity, sleep apnea, diabetes, metabolic syndrome and hyperaldosteronism, characterized by an overexpression of humoral and hormonal factors that are involved in the development and maintenance of TOD. Optimal therapeutic strategies, including pharmacological treatment and innovative invasive methodologies, have been shown to achieve adequate BP control and induce the regression of TOD, thereby potentially improving patient prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23595044     DOI: 10.1038/hr.2013.30

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  21 in total

Review 1.  Reductions of left ventricular mass and atrial size following renal denervation: a meta-analysis.

Authors:  Dasheng Lu; Kai Wang; Qian Liu; Shengchan Wang; Qi Zhang; Qijun Shan
Journal:  Clin Res Cardiol       Date:  2016-02-02       Impact factor: 5.460

2.  Lack of blood pressure control in Italy: room for improvement?

Authors:  M Lorenza Muiesan
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-12-03

3.  Determinants of concentric left ventricular hypertrophy in patients with resistant hypertension: RESIST-POL study.

Authors:  Piotr Dobrowolski; Aleksander Prejbisz; Anna Klisiewicz; Elżbieta Florczak; Justyna Rybicka; Andrzej Januszewicz; Piotr Hoffman
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 4.  Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment.

Authors:  James E Sharman; Pierre Boutouyrie; Stéphane Laurent
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

5.  Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.

Authors:  Yu Hasegawa; Takashi Nakagawa; Ken Uekawa; Mingjie Ma; Bowen Lin; Hiroaki Kusaka; Tetsuji Katayama; Daisuke Sueta; Kensuke Toyama; Nobutaka Koibuchi; Shokei Kim-Mitsuyama
Journal:  Transl Stroke Res       Date:  2014-12-23       Impact factor: 6.829

Review 6.  Prognostic Importance of Ambulatory Blood Pressure Monitoring in Resistant Hypertension: Is It All that Matters?

Authors:  Claudia R L Cardoso; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

Review 7.  Resistant Hypertension: Time to Consider the Best Fifth Anti-Hypertensive Treatment.

Authors:  Andrea Pio-Abreu; Luciano F Drager
Journal:  Curr Hypertens Rep       Date:  2018-06-16       Impact factor: 5.369

8.  Consideration of hypertensive retinopathy as an important end-organ damage in patients with hypertension.

Authors:  S A M Kolman; A M van Sijl; F A van der Sluijs; M A van de Ree
Journal:  J Hum Hypertens       Date:  2016-07-28       Impact factor: 3.012

9.  Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.

Authors:  Shigehiro Karashima; Takashi Yoneda; Mitsuhiro Kometani; Masashi Ohe; Shunsuke Mori; Toshitaka Sawamura; Kenji Furukawa; Takashi Seta; Masakazu Yamagishi; Yoshiyu Takeda
Journal:  Hypertens Res       Date:  2015-11-26       Impact factor: 3.872

Review 10.  Cardiovascular and renal complications in patients with resistant hypertension.

Authors:  Elizabeth S Muxfeldt; Fabio de Souza; Victor S Margallo; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.